Ionis Pharmaceuticals, Inc. IONS Balance Sheet

Ionis pharmaceuticals, inc. (IONS)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Dec'09
ASSETS
Current assets:
Cash and cash equivalents
486	683	247	272	375	278	479	805	227	129	159	132	114	84	84	112	93	128	126	119	148	142	73	94	161	159	256	296	107	124	84	85	56	65	55	85	86	70	100	46	105
Short-term investments
1,897	1,816	1,972	1,989	1,877	1,805	1,479	1,174	807	893	851	722	746	580	603	551	610	650	685	635	546	585	518	496	469	496	414	294	264	249	259	250	277	278	309	310	340	402	397	475	469
Contracts receivable
28	63	49	31	10	12	14	16	36	62	42	50	69	108	8	0	16	11	1	3	26	3	26	41	9	11	12	2	1	0	3	1	1	6	1	5	0	1	1	5	10
Inventories
22	18	19	18	11	8	8	9	9	9	8	6	6	7	9	7	6	6	6	6	6	6	7	7	7	8	7	8	5	6	6	7	4	4	2	2	2	2	1	2	2
Investment in Regulus Therapeutics Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	8	19	24	18	60	93	81	47	56	63	52	65	62	44	33	-	-	-	-	-	-	-	-	-	-	-
Other current assets
122	139	118	102	98	102	97	76	62	73	48	51	25	17	15	17	17	14	29	29	13	15	8	8	9	7	7	5	8	8	7	5	7	5	7	7	7	7	6	7	8
Total current assets
2,558	2,720	2,408	2,414	2,373	2,207	2,079	2,083	1,143	1,168	1,111	964	962	797	730	697	763	837	868	855	835	836	681	705	722	735	763	669	431	423	361	350	347	360	377	410	437	483	507	536	596
Property, plant and equipment, net
163	153	148	135	133	132	132	127	123	121	116	99	95	92	90	90	90	90	89	89	89	88	88	86	86	86	87	88	89	91	92	94	95	96	98	88	37	35	35	36	27
Patents, net
26	25	26	26	25	24	24	23	22	22	21	21	21	20	20	21	20	19	19	19	17	17	16	16	16	15	20	20	19	18	18	17	17	16	16	16	15	15	16	16	15
Long-term deferred tax assets
309	305	284	276	277	290	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licenses, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	2	-	3	3	4	4	5	5	6	6	7	7	8	9	10	11	11	12	12	13	14
Deposits and other assets
32	27	26	25	25	12	12	12	10	10	2	5	5	1	1	1	1	1	9	10	10	13	4	5	5	5	5	5	5	5	6	2	2	2	3	3	3	3	3	3	3
Total assets
3,090	3,233	2,894	2,877	2,835	2,667	2,247	2,247	1,299	1,322	1,252	1,090	1,083	912	843	811	875	947	988	976	955	955	793	817	834	847	881	788	552	545	485	472	470	484	505	529	505	550	575	606	657
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
21	16	13	15	13	28	13	13	13	24	23	13	23	21	15	17	19	28	19	10	16	17	15	13	9	11	8	9	5	10	5	6	5	8	6	3	4	6	3	5	4
Accrued compensation
16	37	24	20	16	29	24	15	12	25	15	10	8	24	11	7	6	16	9	7	5	12	7	6	4	12	6	7	3	7	5	4	3	9	5	4	3	6	4	4	7
Accrued liabilities
62	66	52	49	45	47	50	58	66	66	33	35	30	36	23	18	26	28	24	23	23	30	29	25	27	22	22	16	17	15	11	15	15	18	15	10	8	12	10	13	12
Income taxes payable
32	32	1	4	18	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	8	3	-	-	-	-	-	-	-	-	-	-	-	7
Amount of long-term debt and lease obligation, classified as current, and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
4	2	2	14	14	13	14	1	0	1	0	21	0	1	0	8	8	9	0	1	2	2	3	4	4	4	4	4	4	4	5	5	2	3	4	4	5	5	5	4	4
Current portion of deferred contract revenue
120	118	137	137	144	160	157	160	120	125	104	110	108	51	56	58	63	67	68	58	52	51	51	51	54	48	55	40	35	35	23	22	34	36	52	68	73	74	77	77	75
Total current liabilities
258	273	231	241	252	280	260	248	212	243	177	191	170	133	106	111	124	148	122	102	100	115	107	100	100	97	103	86	70	74	51	55	61	76	83	91	94	105	100	105	111
Long-term deferred contract revenue
467	490	492	516	542	567	523	556	85	108	79	100	115	91	101	112	123	134	149	108	119	127	110	120	130	142	151	75	58	66	36	31	35	17	19	21	32	50	70	90	107
Convertible senior notes
-	-	596	586	577	-	559	550	541	533	524	516	508	500	-	-	-	-	-	-	-	-	155	153	152	-	148	147	145	143	142	-	-	-	-	-	-	-	-	-	-
Amount of long-term debt and lease obligation, classified as noncurrent.
15	15	16	16	16	4	5	14	12	12	13	15	15	15	14	2	2	2	7	7	7	7	4	4	5	6	6	7	6	7	8	9	3	4	4	5	4	5	4	5	11
Long-term financing obligation related to a lease agreement with an affiliate of of BioMed Realty, L.P. for the construction of the company's primary research and development facility in Carlsbad, California due in the next twelve months or greater than the normal operating cycle, if longer. In order to gain early access to the facility, the company modified the lease to accept additional responsibility.
-	-	-	-	-	-	-	-	-	-	0	51	72	72	72	72	72	72	72	71	71	71	71	71	71	71	71	70	70	70	70	70	70	69	68	58	10	10	10	10	-
Long-term mortgage debt
59	59	59	59	59	59	59	59	59	59	59	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2 5/8 percent convertible subordinated notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	146	143	141	139	137	134	132	130	128	125
Investment in Regulus Therapeutics Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5	-5	-5	-4	-3	-2	-1	-0	-5	-4	-
Total liabilities
1,520	1,548	1,397	1,420	1,448	1,480	1,407	1,429	912	957	854	875	882	812	703	699	717	747	742	675	679	698	449	450	460	468	480	387	351	362	315	318	319	313	318	317	278	305	322	344	355
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 139,282,168 and 140,339,615 shares issued and outstanding at March 31, 2020 (unaudited) and December 31, 2019, respectively
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional paid-in capital
2,233	2,203	2,219	2,177	2,117	2,047	2,030	2,011	1,576	1,553	1,528	1,434	1,410	1,311	1,373	1,352	1,331	1,309	1,286	1,269	1,251	1,224	1,365	1,352	1,343	1,324	1,315	1,292	1,091	1,077	1,073	1,019	1,016	1,013	1,009	1,006	1,003	1,000	995	991	985
Accumulated other comprehensive loss
-27	-25	-25	-24	-27	-32	-32	-32	-33	-31	-30	-30	-30	-30	-26	-26	-16	-13	-17	18	47	39	16	24	29	21	29	26	17	12	0	0	-0	-0	-1	0	0	0	1	0	2
Accumulated deficit
-846	-707	-857	-883	-882	-967	-1,287	-1,282	-1,242	-1,241	-1,190	-1,189	-1,177	-1,181	-1,207	-1,214	-1,157	-1,094	-1,023	-987	-1,023	-1,006	-1,037	-1,010	-998	-967	-943	-918	-908	-906	-904	-866	-865	-841	-821	-794	-776	-756	-742	-730	-696
Total Ionis stockholders' equity
1,360	1,471	1,336	1,269	1,207	1,048	710	696	301	281	307	215	201	99	139	111	158	200	245	300	275	257	344	366	374	378	401	401	201	182	170	154	150	171	186	-	-	244	253	262	291
Noncontrolling interest in Akcea Therapeutics, Inc.
210	213	161	187	179	139	129	121	85	84	89	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10
Total stockholders' equity
1,570	1,684	1,497	1,457	1,387	1,187	840	817	387	365	397	-	-	99	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	212	227	-	253	262	302
Total liabilities and stockholders' equity
3,090	3,233	2,894	2,877	2,835	2,667	2,247	2,247	1,299	1,322	1,252	1,090	1,083	912	843	811	875	947	988	976	955	955	793	817	834	847	881	788	552	545	485	472	470	484	505	529	505	550	575	606	657
0.125 percent convertible senior notes due December 2024.
Convertible senior notes
439	434	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1 percent convertible senior notes due November 2021.
Convertible senior notes
279	275	-	-	-	568	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-